ASH 2023 | EP0042, an inhibitor of FLT3 & Aurora kinases, in R/R AML and MDS: insights from a Phase I/IIa trial
David Taussig, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, presents the findings of a Phase I/IIa trial investigating EP0042, an orally bioavailable potent inhibitor of FLT3 and Aurora kinases, as a treatment for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Dr Taussig discusses data from the study’s dose-finding and dose-optimization cohorts, outlining the safety and efficacy of the agent. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Ellipses Pharma
